Wedbush analyst Martin Fan is adding Outperform-rated Zenas BioPharma (ZBIO) to the Wedbush Best Ideas List as the firm sees a buying opportunity for a clinically de-risked drug likely to gain FDA approval, with potential for strong commercial uptake. Additional pipeline assets increase long-term growth prospects while providing downside protection against regulatory or commercial risk, Wedbush adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Zenas BioPharma Adopts Amended Short-Term Incentive Plan
- Zenas BioPharma: Advancing Autoimmune Pipeline and Obexelimab’s Differentiated MS Profile Support Buy Rating and $44 Target
- Zenas BioPharma says obexelimab met primary endpoint in Phase 2 study
- 3 Stocks with a ‘Perfect 10’ Smart Score
- Zenas BioPharma downgraded to Equal Weight from Overweight at Morgan Stanley